MERCAPTOPURINA ACCORD 50mg tablets medication leaflet

L01BB02 mercaptopurine • Antineoplastic and immunomodulating agents | Antimetabolites | Purine analogues

Mercaptopurine is a medication used for the treatment of acute lymphoblastic leukemia and other hematological conditions. It works by inhibiting DNA synthesis in cancer cells, thereby preventing their proliferation.

The medication is taken orally, as directed by a doctor, usually once daily. It is important for patients to follow the treatment regimen and undergo regular check-ups to monitor liver and hematologic function.

Patients should be aware of potential side effects, such as nausea, decreased blood cell counts, or liver impairment. It is important to inform the doctor of any unusual symptoms.

Common side effects include nausea, decreased blood cell counts, and liver impairment. In rare cases, severe reactions such as liver failure or severe infections may occur. Patients should be informed of these risks before use.

General data about MERCAPTOPURINA ACCORD 50mg

Substance: mercaptopurine

Date of last drug list: 01-03-2026

Commercial code: W71593001

Concentration: 50mg

Pharmaceutical form: tablets

Quantity: 24

Product type: generic

Prescription restrictions: P-RF - Medicines prescription that is retained in the pharmacy (not renewable).

Marketing authorisation

Manufacturer: ACCORD HEALTHCARE POLSKA SP. Z.O.O. - POLONIA

Holder: ACCORD HEALTHCARE POLSKA SP. Z O.O. - POLONIA

Number: 16400/2026/01

Shelf life: 2 years

Pharmaceutical forms available for mercaptopurine

Concentrations available for mercaptopurine

20mg/ml, 50mg